Patient preference studies provide evidence about what treatment effects are important to patients, how important they are to patients, and quantify the tradeoffs patients are willing to make between treatment effects. Understanding patient preferences may be especially valuable in the case of multiple myeloma (MM), where the existence of treatments with different effects raises uncertainty about the value of these treatments and their effects to patients.
However, uncertainty exists on how patient preference studies should be designed, conducted and analysed to inform decision-making across the drug life cycle, including drug development decisions by industry, benefit-risk assessment by regulators and health technology assessment (HTA) by HTA bodies and payers. This case study may guide stakeholders (researchers, regulators, payers, patient organisations, clinicians) in conducting or evaluating preference studies and contributes to the debate regarding best practices for preference studies aiming to inform drug decision-making.
The objectives of this study are:
- To determine the relative importance of MM treatment effects according to MM patients
- To compare two methods for quantifying patient preferences: ‘swing weighting’ (SW) and ‘discrete choice experiment’ (DCE)
- To investigate preference heterogeneity; how preferences may be influenced by patient characteristics, namely clinical and demographic characteristics and quality of life
- To investigate the internal validity of responses to DCE and SW questions
- To assess participants’ self-reported comprehension and overall evaluation of the DCE and SW questions
The study consists of two phases:
- A qualitative phase: Focus group discussions using the ‘nominal group technique’ (NGT) with approximately 6 MM patients each, in Belgium, Romania, Finland and Spain, that ask patients to reach consensus on the treatment effects they find most important when considering treatment options.
- A quantitative phase: An online survey among MM patients in Belgium, Romania, Finland and Spain that quantifies the trade-offs they are willing to make between hypothetical treatments that vary with respect to these effects.
- Ana Vallejo (Myeloma Patients Europe)
- Ananda Plate (Myeloma Patients Europe)
- Anneleen Vanhellemont (KU/UZ Leuven)
- Chris De Ronne (CMP Vlaanderen)
- Daniel Coriu (Clinica de Hematologie)
- Diana Preda (Clinica de Hematologie)
- Elena Cabezudo (Hospital de Sant Joan Despí Moisés Broggi. Consorci Sanitari Integral/ICO-Hospitalet)
- Hilde Stevens (I3h, Université libre de Bruxelles (ULB))
- Isabelle Huys (KU Leuven)
- Kate Morgan (Myeloma Patients Europe)
- Martina Vandebroek (KU Leuven)
- Michel Delforge (KU/UZ Leuven)
- Raija Silvennoinen (Helsinki University Hospital)
- Rosanne Janssens (KU Leuven)
- Ruxandra Irimia (Clinica de Hematologie)
- Steven Simoens (KU Leuven)
- Sorina Badelita (Clinica de Hematologie)
Janssens R, Lang T, Vallejo A, Galinsky J, Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study, Frontiers in Medicine, 6 July 2021
|Therapeutic area||Multiple Myeloma (MM)|
|Study led by||KU Leuven|
|PREFER leads team||Rosanne Janssens
|MPLC decision point of interest||Drug development
|PREFER case study acronym||KUL - MM|
|Methods in Qualitative study||Focus group discussions using the "nominal group technique" (NGT)|
|Methods in Quantitative study||Discrete Choice Experiment (DCE)
|End-date qualitative data collection||January 2020|
|End-date quantitative data collection||December 2020|
News from this case study
- PREFER presentation on patient preferences for Multiple Myeloma treatment wins ISPOR award
- Webinar on patient preferences in multiple myeloma now online!
- Patient preferences for multiple myeloma treatment
- What do Multiple Myeloma patients prefer?
- What is the value of treatment effects according to Multiple Myeloma patients?
PREFER case studies
Find out what we have published so far!
We are publishing our results in reports and scientific journals.